2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11B.02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer

P2.11B.02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The document examines the response of patients with advanced non-small cell lung cancer (NSCLC), characterized by STK11 and KEAP1 mutations, to chemoimmunotherapy. These mutations, along with KRAS mutation status, significantly influence treatment efficacy. It was observed that a subset of patients with these mutations still responds effectively to immunotherapy.<br /><br />The study involved analyzing clinicopathologic and genomic data from patients at three academic centers. Utilizing Kaplan-Meier survival analysis, the researchers discovered that patients with tumor mutation burden (TMB) over the 90th percentile and KRAS wild-type status experienced better outcomes. Additionally, in cases of STK11 alterations, those with missense mutations had slightly longer median progression-free survival (mPFS) in univariate models only.<br /><br />PD-L1 expression, KRAS status, and TMB were associated with treatment responses, though the document outlines various statistical analyses including hazard ratios and p-values to emphasize significant findings. For instance, in STK11 mutant NSCLC, missense mutations showed a median PFS of 8.7 months compared to 4.6 months for non-missense mutations, pointing to better outcomes for the former. Conversely, KEAP1 mutations appeared less predictive of response with no significant differentiation between mutation subtypes.<br /><br />The multivariable analysis accounted for age, performance status, treatment line, and specific mutations, offering a comprehensive understanding of factors further influencing patient responses. Overall, the findings emphasize the importance of genetic profiling in guiding NSCLC treatment strategies.<br /><br />The conclusions drawn are particularly relevant for tailoring personalized treatment regimens and highlight the necessity for further research in understanding the molecular underpinnings that dictate the effectiveness of immunotherapy in NSCLC, particularly in the context of these genetic mutations.

Asset Subtitle

Arushi Saini

Meta Tag

Speaker Arushi Saini

Topic Metastatic NSCLC – Immunotherapy

Keywords

NSCLC

STK11 mutations

KEAP1 mutations

KRAS mutation

chemoimmunotherapy

tumor mutation burden

PD-L1 expression

Kaplan-Meier survival analysis

progression-free survival

genetic profiling